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REVIEW OF THE LITERATURE – TUMORIGENESIS IN CELIAC DISEASE  
 
 
1 INTRODUCTION 
 
 
Celiac disease is characterized by the heightened immunological responsiveness to 
ingested gluten from wheat, rye and barley being overrepresented among individuals 
carrying human leucocyte antigen (HLA) DQ2 and DQ8 alleles (Sollid 2002). The 
diagnosis of celiac disease is based on small-bowel mucosal villous atrophy and crypt 
hyperplasia (Kaukinen et al. 2010). Also extensive inflammation in the epithelium and 
lamina propria as well as clinical and histological improvement on a gluten-free diet, are 
essential in diagnostics. Another typical feature for the disease is the presence of 
specific immunoglobulin-A (IgA) class autoantibodies in the serum of patient during a 
gluten-containing diet. The presence of these antibodies that are specific for gluten and 
transglutaminase 2 (TG2) is strictly dependent on dietary exposure to gluten (Sollid 
2002).  
 
Enzymatic function of TG2 has been linked with the pathogenesis of a number of 
diseases besides celiac disease for example certain types of cancer (Molberg et al. 2000; 
Mangala and Mehta, 2005). Various studies have shown that TG2 protein is up-
regulated in cancerous tissue relative to healthy tissue e.g. in pancreatic ductal 
adenocarcinomas and breast cancer (Mehta et al. 2004; Verma et al. 2006). It is also 
known that there is a significant negative correlation between endothelial cell 
angiogenesis as well as TG2 activity and it is suggested that the anti-angiogenic effects 
of celiac patient-derived TG2-targeted autoantibodies are exerted by enhanced 
enzymatic activity of TG2 (Caja et al. 2010).  
 
There have been various studies concerning the connection between celiac disease and 
cancer. All cell types are susceptible to cancer, but especially epithelial cells are 
particularly prone (Syöpätaudit 3. edition 2007). In theory, there is possibility that celiac 
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disease patients would have increased risk for cancer, because their small intestines 
epithelial cells are dividing abnormally fast. 
 
 
2 TUMORIGENESIS  
 
 
2.1 Tumor development 
 
Cancer is one of the leading causes of mortality worldwide and it is predicted that its 
incidence will continue to rise in the next 20 years (Jemal et al. 2008). Nowadays cancer 
is treated by surgery, radiotherapy, chemotherapy, and more recently gene therapy 
(Isola, 2007). Identifying factors that are affecting tumor formation and understanding 
of the cellular mechanism of tumor growth and spread, play key roles in preventing 
cancer and developing new cancer treatments. 
 
It is now well understood that cancer is not a single disease, but many diseases (King 
and Robins, 2006). In the past 50 years, the complexity of cancer has been rendered 
more concrete by a large mount of work that has been done to identify common 
principles of its pathogenesis. Recently, several models of multistep tumorigenesis, via 
discrete genetic changes, have been proposed to explain the transformation of a normal 
cell into a cancer cell. Consolidation of the information that concerns to tumor 
development is difficult and may simplify many details. Still no single model will 
explain the pathogenesis of all human cancers.  
 
Tumorigenesis in humans is a multistep process reflecting genetic alterations that drive 
the progressive transformation of normal human cells into highly malignant derivatives 
(Hanahan and Weinberg, 2000). In normal circumstances cells differentiate to different 
kinds of cells which then form specialised tissues, but in cancer  tissue the cells grow 
abnormally, which is mainly independent of external stimulus and is purposeless and 
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harmful (Isola, 2007). All cell types are susceptible to cancer, but especially epithelial 
cells are prone to change. Tumors are divided to malignant and benign. Benign tumors 
are local, slowly growing and they do not have tendency to invade surrounding tissues 
or metastasize further into the body. Malignant tumors conversely grow fast, spread out 
to their environment and can be fatal to patients. There are six features of malignant 
tumors that are crucial for the tumor growth: ability to produce self-sufficiency of 
growth signals, insensitivity to negative growth-inhibitory signals, ability to avoid 
apoptosis, limitless proliferative capacity, angiogenesis as well as invasion to 
surrounding tissues and formation of metastasis (Hanahan and Weinberg, 2000). The 
ability to deal with immune mechanisms was introduced later on as the seventh feature 
of malignant tumors (Cavallo et al. 2010). 
 
Cancers have similarities, even if every cancer type has many characteristic features of 
their own (King and Robins, 2006). Cancer is considered as disease of the genes, but 
that does not signify the same as a hereditary disease. In some cases a damaged gene is 
directly inherited and in other cases vulnerability to predisposition of carcinogens is 
inherited. Hereditary tendency plays a role in onset of the cancer in 5-10 % of the cases. 
There are many factors, carcinogens, which predispose to cancer. Environmental 
influences are important even though they exert their effects via the genetic machinery 
of the cells (Anand et al. 2008). Longevity and life style factors including tobacco, 
alcohol, sun light, nutrition habits, obesity, and radiation are of major influence. Even 
some medication such as hormones and cytostatics can cause cancer. Hereditary factors, 
viruses and exposure to agents of the environment such as asbestos, some plastic and 
metal compounds, can also cause cancer.  
 
Tumors are known to develop gradually through different mechanisms (Bergers and 
Benjamin, 2002). These stages include oncogene activation, loss of telomerase and 
induction of aneuploidy as critical initiating events. Tumorigenesis results from 
accumulation of errors in vital regulatory pathways. Several mutations are required for 
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carcinogenesis. This involves genes that either gain or lose function as a result of 
mutation. Multiple pathways exist by which a cancer in one cell type is generated and 
cancers arise in single cells. Tumorigenesis is initiated in a single cell, which then 
multiplies and acquires additional changes that give it a survival advantage over its 
neighbours. The altered cells must be amplified to generate billions of cells that 
constitute a cancer. Because this process takes time, old people are more likely to 
develop cancer than young people.  
 
In the majority of situations, the accumulation of errors in the cellular machinery  in 
somatic cells occurs after birth (Folkman, 2006). Some genes, proto-oncogenes, are 
involved specifically in the normal regulation of the cell proliferation. These genes can 
mutate, thus deregulating cell growth and in this case, the genes are termed oncogenes. 
It is now widely accepted that oncogenes can induce tumorigenesis. Cells expressing 
activated oncogenes undergo increased proliferation and decreased apoptosis. 
Additionally, many cancers are generated by a loss of specific genes involved in the 
repair of cell damage, cell death or growth inhibition (Croce, 2008). These are called 
tumor suppressor genes. It is known that cancer can develop from changes/mutations in 
either or both of these regulatory systems. 
 
Cancer development consists of cell and molecule level phenomena (Syöpätaudit 3. 
edition 2007). Developing stages are divided into initation, promotion and progression. 
Mutations occur in the initation phase and the rest of the changes (hormonal promotion, 
genetic instability, immortalization, autonomic cell proliferation, inhibition of apoptosis, 
invasion to connective tissue, angiogenesis) in the promotion or progression phases. 
 
In addition to the genetic changes that occur during transformation, another discrete 
step, induction of tumor vasculature, is required to allow tumour propagation and 
progression (Hanahan and Weinberg, 2000). Like any other tissues, tumors need an 
adequate supply of oxygen, metabolites and an effective way to remove waste products 
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(Papetti et al. 2002). These demands vary between different tumor types and change 
over the course of tumor progression. The critical steps are the access to the host 
vascular system and the generation of a tumor blood supply. Tumors have been 
considered wounds that do not heal and consistent with this idea and microarray 
analyses have shown that a wound response is often associated with cancer malignancy 
(Dvorak 1986; Chang et al. 2004). It has been found that many factors important for 
wound healing play a critical role also in tumor progression.  
 
 
2.2 Tumor angiogenesis 
 
Physiological angiogenesis occurs during the adult life-span after tissue injury and in 
wound healing (Papetti et al. 2002). The main task for new vessels is to provide 
nutrients and oxygen to support and promote tissue formation and facilitate the 
clearance of debris to restore the blood flow to tissues. Angiogenesis is also involved 
during pregnancy in building placenta and during ovulation maturing the egg and 
rebuilding the uterus lining. 
 
Vasculogenesis is a complex process in which the endothelial cells assemble into 
tubules which merge and form the primary vascular plexus of the embryo (Choi et al. 
1998). By this process blood vessels are originally formed. The common precursors for 
endothelial and hematopoietic cells are multipotent hemangioblasts derived from 
mesodermal cells in the embryo. Endothelial cells can differentiate into arterial or 
venous endothelial cells, neonatal retina and into heart of an adult human during this 
embryonal development. The remodelling of the primary vessels into veins, arteries and 
capillaries is called angiogenesis and in normal growth this kind of expanding 
vasculature provides essential nutrients to enlarging tissues (Risau, 1997). Angiogenesis 
is also definied as the formation of new capillaries from the pre-existing ones. 
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There are at least three, maybe even four different mechanism how the angiogenesis 
process can take place: sprouting angiogenesis, incorporation of circulating endothelial 
progenitor cells into growing vessels, intussusception and vessel elongation (Risau, 
1997). In sprouting angiogenesis, the blood vessels arise from pre-existing capillaries in 
a multistep process which depends on the coordination of several independent phases 
(see Figure 1). Endothelial cell activation, matrix degradation and vessels 
destabilisation initiate this process. Thereafter the endothelial cells begin to proliferate 
and migrate out through the dissolved holes in the vessel walls into perivascular space. 
Adhesion molecules serve as grappling hooks to help pull the new blood vessel sprout 
forward and endothelial cells migrate along this forming sprout and invade the 
underlying mesenchymal tissue simultaneously recruiting mesenchymal cells from the 
surrounding tissue. The pericytes have to brake the basement membrane barrier so that 
they could migrate (Papetti et al. 2002). The basement membrane is produced by 
endothelial cells and pericytes. This membrane regulates the stability of vessels and also 
blocks regression of the vasculature. 
 
Vascular endothelial growth factor (VEGF) pathway is one of the key regulators of 
angiogenesis (Hicklin et al. 2005). Activation of the VEGF-receptor activates a network 
of signaling processes that promote endothelial cell growth, survival from pre-existing 
vasculature, and migration. Furthermore, VEGF mediates vessel permeability. VEGF 
has also a crucial role in mobilization of endothelial progenitor cells to distant sites of 
neovascularization.  
 
Ricci-Vitiani and colleagues described (2010) a new mechanism for tumour 
vasculogenesis, which might explain the presence of cancer-derived endothelial-like 
cells in several malignancies (Ricci-Vitiani et al. 2010). They studied glioblastoma 
which is highly angiogenetic malignancy and formed by vessels which are thought to 
arise by sprouting of pre-existing brain capillaries. They discovered that a population of 
glioblastoma stem-like cells (GSCs) maintains glioblastomas indicates that the progeny  
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Figure 1. Schematic description of the angiogenic switch. The angiogenic switch is an 
activation step in tumor development that may take place at different stages in the tumor 
progression pathway. The nature of the tumor and its microenvironment have effect on 
this pathway. Most tumors start growing as avascular, dormant nodules (a) until they 
reach a steady-state level of apoptosing and proliferating cells. The initiation of 
angiogenesis is essential to the exponential tumor growth. The switch begins with vessel 
dilatation and perivascular detachment (b), followed by angiogenic sprouting (c), new 
vessel formation and maturation, and recruiting of perivascular cells (d). Blood-vessel 
formation continues as long as the tumor grows providing essential nutrients and 
oxygen (e) (Bergers and Benjamin 2002). 
 
 
of these cells might not be confined to the neural lineage. This connection between 
neural stem cells and the endothelial compartment indicates appears to be critical in 
glioblastoma, where cancer stem cells closely interact with the vascular niche and 
promote angiogenesis through the release of VEGF. They showed that a variable 
number endothelial cells in glioblastoma have the same genomic alteration as tumour 
cells, indicating that a significant portion of the vascular endothelium has a neoplastic 
origin (Ricci-Vitiani et al. 2010). The vascular endothelium contained a subset of 
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tumorigenic cells that produced highly vascularized anaplastic tumours with areas of 
vasculogenic mimicry in immunocompromised mice and selective targeting of 
endothelial cells generated by GSCs in mouse xenografts resulted in tumour reduction 
and degeneration, indicating the functional relevance of the GSC-derived endothelial 
vessels. 
 
Because blood vessels are present nearly everywhere in human body, it is rational that in 
many serious disease conditions the vasculature is altered due to changed regulation of 
angiogenesis (Carmeliet et al. 2003). Already in 1971 Folkman proposed that tumor 
growth is dependent on angiogenesis (Folkman, 1971). In tumorgenesis the problem is 
excessive angiogenesis, which creates better condition for tumor to grow: new blood 
vessels provide nutrients to diseased tissue and thus participate in destroying the normal 
tissue (Carmeliet et al. 2003). New vessels also provide a route for invasive tumor cells 
to enter the circulation. Tumors which have a high microvascular density tend to be 
more aggressive and prone to metastases (Baluk et al. 2005).  
 
Mammalian cells require oxygen and nutrients for their survival (Carmeliet and Jain, 
2000). That is why they are located within 100 to 200 μm of blood vessels, which is the 
diffusion limit for oxygen. Tumors cannot grow beyond a critical size or metastasize to 
another organ without blood vessels. Multicellular organisms growing beyond this 
critical size must recruit blood vessels by vasculogenesis and angiogenesis (Bergers and 
Benjamin, 2003). Angiogenesis is dependent and regulated by a balance between pro- 
and antiangiogenic molecules. In various diseases, especially in cancer,  this balance is 
derailed. 
 
 
 
Tumor cell proliferation and angiogenesis are required in the generation of lethal tumor 
mass (Folkman, 2006). In fact, endothelial cell proliferation is a prerequisite, but not the 
only component of angiogenesis. In the absence of angiogenesis, tumor cell 
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proliferation alone can give rise to latent, microscopic tumors less than one mm3 
(Folkman, 2000). These kind of in situ cancers are harmless to the host. Actually tumor 
cell proliferation remains constant at all tumor volumes (Streit et al. 1999). 
 
If oncogene is transfected into tumor cells, angiogenic activity is significantly increased 
by augmented expression of VEGF and decreased expression of antiangiogenic proteins 
like thrombosponin-1 (Watnick et al. 2003). Experiments show that oncogene activation 
can induce increased proliferation over apoptosis in a tumor as well as increased 
angiogenic activity (Folkman, 2006). This indicates that complete blockade of the 
angiogenic component of oncogene expression will leave only a residual microscopic, 
nonangiogenic tumor that is harmless to the host, despite the high proliferation rate of 
its tumor cells. 
 
It is generally accepted that the angiogenic “switch” is “on” when the net balance is in 
favour of angiogenesis and “off” when the effect of pro-angiogenic molecules is 
balanced by anti-angiogenic molecules (Hanahan et al. 2000). In other words, the 
effects of angiogenesis depend on pro- and antiangiogenic molecules and their mutual 
balance. Many signals that trigger this “switch”, that have impact on the balance have 
been discovered and they include metabolic stress (for example low pH), mechanical 
stress (pressure generated by proliferating cells), immune/inflammatory response 
(inflammatory cells that have infiltrated the tissue), and genetic mutations (activation of 
oncogenes or deletion of tumor suppressor genes that control production of 
angiogenesis regulators) (Carmeliet, 1999; Carmeliet and Jain, 2000). Pro- and 
antiangiogenic molecules can drift from cancer cells and tumor type and site can change 
depend on their relative contribution and it may change with tumor growth, regression 
and relapse. In tumors the expression of these regulators is not as well coordinated as in 
normal physiological angiogenesis, and their mechanism of action is still poorly 
understood. Also tumor vessels lack protective mechanisms that normal vessels acquire 
during growth and endothelial cells do not always form homogenous layer on the vessel 
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wall (Carmeliet, 1999). The vessel wall maybe lined with only cancer cells or a mosaic 
of cancer and endothelial cells. 
 
 
3 TRANSGLUTAMINASES  
 
 
3.1 Overview of transglutaminases 
 
In 1957 Clarke and co-workers introduced the term transglutaminase (TG) when they 
found transamidating activity in the guinea-pig liver (Clarke et al.1957). Nine TGs have 
been identified, protein 4.2 and eight enzymes designated factor XIII-A, in mammals 
including humans, but they are also found in plants, fish, birds, and micro-organism 
(Mehta et al. 2010; Griffin et al. 2002). All TG family members have the same basic 
structure (Iismaa et al. 2009). TGs are inactive under normal conditions and activated 
only following disruptions in physiological homeostatic mechanism. For their activity 
TGs require the binding of Ca2+ and then they can catalyze posttranslational 
modification of proteins via ε–(γ-glutamyl)lysine isopeptide bonds or through 
incorporating primary amines at selected peptide-bound glutamine residues. Reaction 
products are often cross-linked high-molecular-mass protein aggregates, which can also 
be further polymerized. Each TG has its own specific amino acid target(s) for cross-
linking and three of them (TG2, TG3 and TG5) are inhibited by guanosine-5'-
triphosphate (GTP) (Collighan and Griffin, 2009). 
  
Protein cross-linking is the best known reaction of TGs, but they mediate at least five 
other posttranslational modification reactions (Iismaa et al. 2009). These reactions can 
be divided into three types: hydrolysis, transamidation and esterification, are essential 
biological processes. The amine substrates of TGs have many physiological functions. 
They act as “biological glue” in cell death, cell-matrix interactions when stabilizing 
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epidermis and hair and in the general maintenance of tissue integrity, blood coagulation, 
skin barrier formation and extracellular matrix assembly (Fesus and Piacentini, 2002; 
Iismaa et al. 2009). These reactions also contribute to the pathophysiology of various 
inflammatory, autoimmune and degenerative conditions.  
 
3.2 Transglutaminase 2 
 
TG2 is the most common transglutaminase and the first transglutaminase identified 
(Fesus and Piacentini, 2002). TG2 is composed of 686 amino acids and it size is 76 
kDa. TG2 has four sequential and structurally distinct domains: an N-terminal β-
sandwich with fibronectin and integrin binding site, catalytic core which contains the 
catalytic triad for the acyl-transfer reaction and a conserved Trp essential for this 
catalytic activity and two C-terminal β-barrel domains, with the second containing a 
phospolipase C binding sequence (Iismaa et al. 2009; Fesus and Piacentini, 2002). TG2 
has unique guanidine nucleotide-binding site located in a cleft between catalytic core 
and the first β-barrel. 
 
TG2 is mainly an intracellular protein and locating primarily in the cytoplasm and a 
small portion in the nucleus. In addition, TG2 is present on the cell surface and in the 
extracellular matrix (ECM) (Upchurch et al. 1991; Verderio et al. 1998). TG2 has 
several distinct biochemical functions at its various locations (see Figure 2) (Fesus and 
Piacentini, 2002). In addition to crosslinking, TG2 can modify proteins by amine 
incorporation and deamidation, and by acting as an isopeptidase in a Ca2+-dependent 
manner. TG2 mediates the interaction of integrins with fibronectin and crosslinks 
proteins of the ECM when it is externalized from cells. It also acts as a G protein and 
binds and hydrolyzes guanosine-5'-triphosphate (GTP). The guanosine-5'-
diphosphate(GDP)/GTP-bound form of TG2 cannot act as a transglutaminase. This 
inhibition is reversed by Ca2+, which serves as a switch between the two distinct 
functions. 
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Figure 2. Biochemical functions of transglutaminase 2 (TG2). TG2 can catalyze Ca2+-
dependent acyl-transfer reaction between γ-carboxamide group of a specific protein-
bound glutamine and either the ε-amino group of a distinct protein-bound lysine residue 
or primary amines. Water can replace amine donor substrates. TG2 has Ca2+-dependent 
isopeptidase activity and it can hydrolyse γ:ε isopeptides, at least in vitro. Furthermore 
TG2 can be exposed on the external leaflet of the plasma membrane. The presence of 
TG2 outside the cell has been proposed to depend on its interaction with fibronectin and 
integrins. TG2 binds and thus activates phospholipase C following stimulation of 
numerous kinds of cell surface receptors; its endogenous GTPase activity ensures 
proper regulation of transmembrane signalling through these receptors. Functions of 
TG2 are conducted in the nucleus (N), the cytosol (C), at the cell membrane (M) and in 
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the extracellular space (E). All functions have been shown to occur in intact cells and/or 
tissues, except isopeptidase activity (Figure adapted from Fesus and Piacentini 2002). 
 
 
The TG2 has multiple roles in cells. At membrane locations, TG2 establishes 
transmitting signals from seven-transmembrane helix receptors to phospolipase C 
(Iismaa et al. 2000). The Ca2+ requirement for the transglutaminase activity might be 
reduced by the interaction of TG2 with specific molecules and this activity is influenced 
by nitric oxide (Fesus and Piacentini, 2002). Ca2+ activated TG2 interacts and modifies 
major components of the cytoskeleton. TG2-dependent transamidation of ras homology 
gene family, member A (RhoA), in response to retinoic acid (RA) treatment, results in 
the increased binding to RhoA GTPase to Rho-associated protein kinase 2 (ROCK-2), 
phosphorylation of vimentin and autophosphorylation of ROCK-2 (Singh et al. 2001). 
These can lead to to the formation of stress fibers and increased cell adhesion and they 
can be prevented by TG2 inhibition (Collighan and Griffin, 2009).  
 
 
TG2 is translocated in the nucleus under certain conditions where it can act as a G 
protein or as a transamidase. This suggests that TG2 may have a direct role in chromatin 
modification and/or regulation of gene expression (Fesus and Piacentini, 2002). In the 
cell undergoing apoptosis TG2 is induced in vivo, and lately it has been reported that 
TG2 sensitizes cells for apoptosis by interacting with mitochondria (Piacentini et al. 
2002). In the late stage of apoptosis, the massice increase of cytosolic Ca2+ determines 
the switch of TG2 to its crosslinking configuration in all subcellular compartments. This 
leads to extensive polymerization of intracellular proteins and these protein lumps 
stabilize the structure of the dying cell and limiting the release of harmful intracellular 
components and consequently inflammatory or autoimmune responses (Piredda et al. 
1997). 
 
On the cell surface, the integrin-bound TG2 provides a binding site for fibronectin 
(Fesus and Piacentini, 2002). TG2 binds fibronectin with a high affinity. On the surface 
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of different cell types, 5-40% of β1 integrins may be complexed with TG2. This 
interaction takes place mainly at the extracellular domains of integrin β subunits, does 
not require crosslinking activity and facilitates spreading, adhesion and motility of cells. 
TG2 is involved in wound healing, angiogenesis and the assembly, remodelling and 
stabilization of the ECM in numerous tissues (Aeschlimann et al. 1995; Fesus and 
Piacentini, 2002; Haroon et al. 1999). The secreted enzyme promote the covalent 
modification and activation of numerous growth factors, for example TGFβ, which 
contributes transcriptional regulation of ECM genes and of TG2 itself. 
 
Enzymatic function of TG2 has been linked to the pathogenesis of a number of diseases: 
celiac disease (Molberg et al. 2000), diabetes (Bernassola et al. 2002), 
neurodegenerative disorders (Hoffner and Djian, 2005), and certain types of cancer 
(Mangala and Mehta, 2005). Inhibition of the TG2 of active site may offer a potential 
target to treat these diseases.  
 
 
3.2.1 Transglutaminase 2 in tumorigenesis 
 
A vital property of the malignant tumor cells is their ability to survive in hostile host 
environments when they pass through the lymphatic system or the bloodstream in their 
attempt to colonize at distant sites (Mangala et al. 2005). The survival of tumor cells 
which have escaped into the vasculature depends on their ability to dock with and attach 
to tissues where they are able to metastasize (Advances in cancer research volume 43, 
1985). TG2 expression is upregulated in response to tissue injury and other stressors in 
normal tissues, where TG2 plays a role in restoring the normal homeostasis (Kumar et 
al. 2010). In pathological conditions, such as cancer, TG2 expression within the cell or 
its microenvironment modulates intracellular signaling and promotes cell adhesion 
(Fesus and Piacentini, 2002). For instance, intracellular TG2 is known to activate FAK 
and NF-κB (Mann et al. 2006). In the extracellular environment, TG2 can modify the 
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extracellular matrix proteins and alter cell-cell and cell-matrix interactions (Kumar et al. 
2010). Although, there is evidence of a connection between TG2, drug resistance, and 
metastasis of cancer cells, the mechanisms behind these events remain largely unknown. 
 
A down-regulation of TG2 expression has been found in certain types of cancer (Jones 
et al. 2006).  Xu and co-workers suggested that TG2 can act as a tumor suppressing 
protein through its interaction with GPR56 (Xu et al. 2006; Xu and Hynes, 2007).  
Verma and co-workers suggest that TG2 expression activates the FAK through a 
mechanism independent of its enzymatic activity (Verma et al. 2006). Activated FAK 
then activates anti-apoptotic pathways and that may lead to uncontrolled cell growth if 
keenly activated (Lee et al. 2004; Mann et al. 2006). Therefore, enzymatically active 
TG2 appears to have both proapoptotic and anti-apoptotic effects on cancer cells 
depending upon the assay.  
 
Various studies have shown that the TG2 protein is up-regulated in cancers such as 
glioblastomas, malignant melanomas and pancreatic ductal adenocarcinomas (Yuan et 
al. 2006; Fok et al. 2006; Verma et al. 2006). Metastatic breast cancer and malignant 
melanoma show substantial higher TG2 expression than their primary tumors (Mehta et 
al. 2004, Fok et al. 2006). TG2 expression has been shown to correlate positively with 
the propensity of human tumors to metastasize (Mangala et al. 2005). Increased 
expression of TG2 in cancer cells also confers resistance to cytostatic drugs and 
promotes invasive potential of cells and it has been linked to poor patient survival. 
These findings suggest a link between chronic inflammation, TG2 and progression of 
metastatic and drug-resistant cancer. While siRNA down-regulation of TG2 protein 
expression levels or treatment with TG2 inhibitors may sensitize cells to apoptosis and 
decreased invasion, TG2 has been shown to exert anti-apoptotic effects in certain cell 
types (Mangala et al. 2007). TG2 can be involved in the relay of anti-growth signals 
during tumour growth (Kotsakis and Griffin, 2007).  
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The relevance of TG2 to cancer biology may depend on the type of cancer, the cancer 
cell type, the location and the stage of the cancer and, more importantly, on whether 
TG2 resides inside or outside the cell (Siegel and Khosla, 2007). Nuclear, cytosolic, 
membranous or extracellular TG2 may impact cell growth, survival or invasion in 
completely different way. It is hard to predict whether certain cancers are dependent 
upon the enzymatic activity of TG2 or not. Some mechanisms have been proposed that 
would explain why TG2 promotes oncogenesis in certain cell or tissue types, but no 
unifying mechanism is known. Accurate understanding of the expression and function 
of TG2 in the context of cancer stage and type is important for implementation of TG2-
based interventions to disturpt malignant invasion, growth and survival. 
 
 
3.2.2 Transglutaminase 2 in angiogenesis     
 
Angiogenesis is crucial to solid tumor growth, because tumors cannot grow beyond  a 
critical size (< 1mm3) or metastasize, unless they are located within 100 to 200 μm of 
blood vessels, which is the diffusion limit for oxygen without blood vessels (Carmeliet 
and Jain, 2000; Jones et al. 2006). Multicellular organisms which grow beyond this 
critical size must recruit blood vessels by angiogenesis (Bergers and Benjamin, 2003). 
TG2 has been reported both to enhance and to inhibit angiogenesis (Haroon et al. 1999; 
Bergamini et al. 2005; Jones et al. 2006).  
 
TG2 catalyzes the multimerization of proteins by generating ε–(γ-glutamyl)lysine 
isopeptide bonds. Many ECM proteins are substrates of the enzyme and the crosslinking 
of these proteins by endothelial cell TG2 is thought to stabilize the basement membrane 
(Lorand and Graham, 2003, Jones et al. 2006; Bakker et al. 2008). Inappropriate and 
continuous crosslinking of the ECM by TG2 can lead to ECM accumulation and fibrosis 
in different tissues (Jones et al. 2006). TG2 is thought to be involved in cell migration 
and adhesion on the cell surface (Jones et al. 1997; Bergamini et al. 2005). Even if some 
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of these proposed functions of TG2 are similar to the critical steps involved in 
angiogenesis, the role of TG2 in this process is poorly understood, but something is 
known. TG2 may be a mediator of angiogenesis either directly by its covalent 
modification of proteins or indirectly by modifying TGF-β function (Kotsakis and 
Griffin, 2007). TGF-β function is essential for normal vascular development. Haroon 
and co-workers established that TG2 protein and activity are expressed and function 
within the wound at sites of neovascularization and formation of granulation tissue 
(Haroon et al. 1999). TG2 stabilizes the structures by covalently ligating extracellular 
matrix molecules. Unexpectedly indeed, TG2 knockout mice can live almost normal life 
without any vascular abnormalities (Nanda et al. 2001).  
 
A direct involvement of TG2 in angiogenesis has been shown in the rat skin wound 
healing assays, and inhibition of angiogenesis shown in in vitro angiogenesis model. 
Administration of active TG2 caused accumulation of extracellular matrix which lead to 
suppressions of endothelial tube formation without causing cell death (Jones et al. 
2006). A less well-defined role TG2 is modulation of endothelial barrier function (Sane 
et al. 2007). There is a significant negative correlation between endothelial cell 
angiogenesis and TG2 activity (Caja et al. 2010). Apparently the anti-angiogenic effects 
of celiac patient-derived TG2-targeted autoantibodies are exerted by enhanced 
enzymatic activity of TG2. 
 
Recent data have implicated TG2 in several intra- and extracellular processes that are 
critical for wound healing including apoptosis, osteogenesis, cellular signaling, and cell 
adhesion (Haroon et al. 1999). Even novel antiangiogenic agents have been developed. 
They interfere with endothelial cell proliferation, migration, and invasion to control 
inappropriate angiogenesis (Perry 2010). 
 
 
 
 
18 
 
Celiac disease -specific TG2 -targeted autoantibodies disturb several steps of 
angiogensis: endothelial sprouting and the migration of both endothelial and vascular 
mesenchymal cells (Myrsky et al. 2008). Moreover, the autoantibodies cause 
disorganization of the actin cytoskeleton in the capillary cells that account most 
probably for the defective cellular migration. Celiac disease autoantibodies recognizing 
TG2 inhibit angiogenesis in vitro. Celiac disease-derived monoclonal TG2-targeted 
antibodies produced by a recombination technology inhibit endothelial tubule formation 
and enhanced the cross-linking activity of TG2. When this enzymatic activity is 
inhibited by site-directed irreversible TG2 inhibitors in the presence of autoantibodies in 
vitro angiogenesis is normalized (Caja et al. 2010). 
 
 
 
 
4 CELIAC DISEASE   
 
 
4.1 General features 
 
Celiac disease is common, worldwide chronic disease and found specially in 
populations of European descent (Jabri et al. 2005; Ciclitira and Moodie, 2003). It is 
more common among females than males (Ciclitira and Moodie, 2003). Celiac disease 
is one of the most common lifelong disorders in Europe (Mustalahti et al. 2010). It 
affects around 1 % of the general population in both children and adults. In some 
countries prevalence of the condition is more than 2 % of the population, for example in 
Finland (Lohi et al. 2007). Up to 75-90 % of all celiac disease cases remain 
undiagnosed due to absent or atypical symptoms. 
 
The total prevalence of celiac disease seems to have doubled in Finland during the last 
two decades:  the prevalence among the adults in 1978-1980 was approximately 1 % 
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and in years 2000-2001 2 % (Lohi et al. 2007). An increased prevalence cannot be 
attributed to the better detection rate alone even if diagnosis of celiac disease has 
improved significantly. The environmental factors like the type of cow’s milk formulas, 
breast feeding, age at gluten introduction, quantity of gluten and quantity of wheat 
gluten, and quality of cereals are factors that may influence the clinical manifestation of 
the disease (Mäki et al. 1992). It seems that a delayed exposure to gluten could prevent 
the onset of the disease. The prevalence of transglutaminase antibodies and celiac 
disease is lower in Russian Karelia than in Finland (Kondrashova et al. 2008). 
Kondrashova and co-workers (2008) suggest that it might be associated with a 
protective environment characterized by lower wealth and standard of hygiene in 
Karelia. 
 
Celiac disease is an acquired disorder. The diagnosis remains a challenge for the health 
care system due to mild or atypical symptoms (Kaukinen et al. 2010). There are many 
disease that similar symptoms as celiac disease. Even symptoms among celiac patients 
vary highly (Alaedini and Green, 2005). The characteristic features of this disorder 
include gluten-dependent small-bowel mucosal damage with villous atrophy and crypt 
hyperplasia which improve, clinically and histologically, when gluten-free diet is 
followed.  
 
Celiac disease used to be characterized by malabsorption, diarrhoea and failure to thrive 
in childhood, but during the last decades the clinical features of celiac disease has 
changed essentially (Kaukinen et al. 2010). The age at diagnosis has shifted upward and 
symptoms have become minor. In some cases, the patients are totally asymptomatic 
(Fasano and Catassi, 2001). Already in the late 1980´s Mäki and co-workers reported an 
5-6 year up-shift of age at diagnosis in children in Finland (Mäki et al. 1988). They also 
observed that fewer than 50 % of new cases had typical gastrointestinal symptoms. 
Reports from Europe and North America also show that almost 50 % of patients with 
newly diagnosed celiac disease do not present gastrointestinal symptoms (Fasano and 
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Catassi, 2001). Even if celiac disease mainly affects the gastrointestinal tract, it may 
also have numerous extraintestinal manifestations. The clinical manifestations of celiac 
disease vary clearly with the age of the patient and the duration and extent of disease.  
 
An asymptomatic form of celiac disease is characterized by the presence of histologic 
changes in intestine (Ferguson et al. 1993). Most of these cases have been identified 
through screening programs, involving apparently healthy subjects (individuals who are 
at increased risk of developing celiac disease by hereditary reason or other reasons). The 
clinical anamnesis may reveal that many of these silent cases have low psychophysical 
well-being. Most common findings are iron deficiency, behavioral disturbances, such as 
tendency to depression, impaired physical fitness, feeling always tired and reduced bone 
mineral density (Mäki et al. 1988; Kaukinen et al. 2010). Osteopenia is common finding 
from asymptomatic celiac disease patient (Mustalahti et al. 1999). Subjects with 
asymptomatic celiac disease are vulnerable to develop the same long-term 
complications as the individuals with typical symptoms (Fasano 2001). The change 
towards milder symptoms might be partly explained by an earlier and improved 
diagnosis (Kaukinen et al. 2010). 
 
Dermatitis herpetiformis, “skin celiac disease”, is the best known extraintestinal 
manifestation of celiac disease. It is a blistering skin disease characterized by 
pathognomonic granular immunoglobulin A (IgA) deposits even in uninvolved skin (Fry 
1995). Typical sites of the rash are the elbows and buttocks. Varying degree of 
enteropathy, ranging all the way from the infiltrative-type lesion to flat mucosa, can be 
found on small intestinal biopsy in almost all of the dermatological cases but intestinal 
symptoms are still rare.  
 
Iron deficiency can be the only sign of celiac disease (Murray 2005; Carroccio et al. 
1998). Short stature is also well described as a single symptom of celiac disease. As 
many as 9–10 % of the children and adolescent with “idiopathic” short stature have 
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celiac disease (Fasano and Catassi, 2001; Stenhammar et al. 1986). The bone age and 
growth velocity are substantially impaired in these patients. Other extraintestinal 
manifestations are dental enamel hypoplasia (up to 30 %), occasional idiopathic chronic 
hepatitis, osteoporosis (up to 26 %) and osteopenia (40 %) (Aine 1986; Leonardi et al. 
1990; Mora et al. 1999). Furthermore, approximately 10 % of celiac disease patients 
suffer from neurological symptoms like gluten ataxia and neuropatia (Hadjivassiliou et 
al. 1996; Hadjivassiliou et al. 2008). Beside these multiple symptoms the patients do 
have TG2-targeted autoantibody deposits in the brain around blood vessels but also in 
small intestinal mucosa (Hadjivassiliou et al. 2006). There are even more 
extragastrointestinal symptoms: a delay in onset of puberty secondary to celiac disease, 
recurrent abortions and reduced fertility  have also been reported (Gasbarrini et al. 2000; 
Kaukinen et al. 2010). 
 
In 1969, the European Society of Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) defined the diagnostic criteria for celiac disease and later some revision 
was made (Walker-Smith et al. 1990). The diagnostic criteria for celiac disease are 
based on the finding of small-bowel mucosal villous atrophy and crypt hyperplasia, with 
inflammation in the epithelium and lamina propria and clinical and histological 
improvement on a gluten free diet (Kaukinen et al. 2010). Endoscopy is unpleasant but 
necessaryprocedure to get the right diagnosis and small intestine biopsies are considered 
the gold standard for the diagnosis of celiac disease (Walker-Smith et al. 1990).  
Viewing good biopsies histologically is challenging and requires an experienced 
clinician. If dermatitis herpetiformis is suspected, a skin biopsy should be taken from 
the uninvolved perilesional skin. 
 
 
When symptoms are atypical or subtle or if a risk group is being examined, screening 
with serum endomysial (EmA) or TG2 antibodies is recommended. The sensitivity of 
these tests is 90 %-100 % and specifity is near 100 % (Collin et al. 2005). It has been 
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suggested that EmA could be used as a confirmatory test after initial TG antibody 
screening because the specifity of EmA assays is higher than TG2 antibody (Rostom et 
al. 2005). These antibodies have been shown to be better than  the earlier anti-gliadin 
antibodies (Mäki et al. 2003). Total IgA levels should be measured or an IgG antibody 
test should be added to improve the sensitivity in some cases, because 2-3 % of 
individuals with celiac disease also have selective IgA deficiency. The newly developed 
deamidated gliadin peptide antibody tests are advisable and they appear to to have 
almost same sensitivity and specifity than EmA and TG2 antibody tests (Kaukinen et al. 
2007). Still they are not used because they wait for a large-scale validation. 
 
A treatment of celiac disease is simple. Elimination of gluten from diet is the only way. 
Strict gluten-free diet is sometimes hard to follow and therefore it is important to search 
also other treatments, like silencing of the immune response. Unfortunately gluten-free 
diet does not have desired impact on the treatment of neurological disorders, gluten 
ataxia and polyneuropatia, but osteopenia is known to recover on gluten-free diet 
(Hadjivassiliou et al. 2003; Mustalahti et al. 1999). In dermatitis herpetiformis patients, 
both the enteropathy and the rash clear slowly with a gluten-free diet together with 
dapson medication (Reunala and Collin, 1997; Kárpáti 2004).   
 
 
4.2 Malignancies in celiac disease  
 
Connection between celiac disease and cancer was established long time ago. Fairley 
and Mackie were the first to note this association in 1937 (Fairley and Mackie, 1937). 
They described six patients with malignant lymphoma of the small intestine. Studies 
before 1990´s suggested that celiac disease or dermatitis herpetiformis carry two- to six- 
fold increased risk of malignancy and  that the spectrum of celiac disease-associated 
cancers was wide (Holmes et al. 1976; Leonard et al. 1983; Swinson et al. 1983).  
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Recent population studies have shown that the risk of malignancy in celiac patients is 
slightly higher than in the normal population. The risk also reduced to the normal level 
after several years on a gluten-free diet (Holmes et al. 1989; van Heel and West, 2006). 
The declining risk of all malignancies by a gluten-free diet over time was shown in a  
cohort study by Askling and co-workers (Askling et al. 2002). Their study indicates that 
the total cancer occurrence is temporarily elevated.  
 
In 1960´s, it was suggested that lymphoma is a complication of celiac disease and after 
that the association of particularly non-Hodgkin lymphoma (NHL) has been shown in 
several studies (Fairley and Mackie, 1937; Gough et al. 1962;   Askling et al. 2002; 
Catassi et al, 2005; Viljamaa et al. 2006). In the earlier small studies, the connection 
was evident, but in recent larger studies the risk estimates have been considerably lower.  
In recent years it has been approximately four-fold compared to over 13-fold risk in 
cases diagnosed about 20 years earlier (Gao et al. 2009). The risk of NHL seems to be 
most significant during the first years after diagnosis and at a higher age (Cooper et al. 
1982; Gao et al. 2009). T-cell lymphoma is rare but also typical among celiac disease 
patients (Cellier et al. 2000). Uncontrolled activation of intraepithelial lymphocytes 
(IELs) causes these lymphomas, and provokes a severe enteropathy refractory to the 
gluten-free diet. 
 
Many malignancies of the gastrointestinal tract have repeatedly been shown to be 
associated with celiac disease, including adenocarcinoma of the pharynx, mouth, and 
small intestine as well as lymphoma and adenocarcinoma of the small intestine (Holmes 
et al. 1976; Leonard et al. 1983; Swinson et al. 198; Askling et al. 2002; Kumar 2006). 
The risk of developing small intestinal cancer increases if celiac disease is undiagnosed 
or the is a failure to maintain gluten free diet (Kumar 2006). One study highlighted  
unrecognised but markedly increased (liver cancer) and reduced (breast cancer) risks for 
specified cancers among individuals with celiac disease (Askling et al. 2002). The latter 
finding has been explained with the lower body weight or the lower frequency of 
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smoking in celiacs. The reduced risk was observed in all age groups (West et al. 2004). 
This might also be caused by chance, but a similar trend has been described in some 
populations with immune suppression or other types of immune dysfunction (Ekbom et 
al. 1991; Stewart et al. 1995).  
 
It has been suggested that celiac disease may itself increase the risk for cancers of the 
upper-gastrointestinal tract: activated T-cells in celiac disease release proinflammatory 
cytokines not necessarily confined to the small intestine (Askling et al. 2002). 
Nutritional deficiences secondary to celiac disease or its dietary treatment also may 
increase the risk of at least oropharyngeal and esophageal cancers. Increased primary 
liver and pancreatic cancer risk was also found. The mechanisms behind malignancies 
development are not known. Chronic inflammation, release of proinflammatory 
cytokines, increased intestinal permeability of environmental carcinogens, immune 
surveillance problems, chronic antigenic stimulation, and nutritional deficiencies caused 
by the disease or the gluten- free diet  have been proposed (Green et al. 2003). The long 
latency between celiac disease and cancer development refers to a multistep process 
which requires a sequential accumulation of several carcinogenetic mutations.  
 
 
4.3 Pathogenesis 
 
The main causes of celiac disease are genetic predisposition, dietary gluten and immune 
reaction which is caused by genetic predisposition and gluten together (Maiuri et al. 
2003). The exact pathogenic mechanism is not known, but it is thought to progress 
through both innate and adaptive immunity mechanisms. 
 
A familial occurence of celiac disease refers that genetic factors play a role (Sollid 
2002). Celiac disease is associated with specific HLA class II haplotypes DQ2 and DQ8. 
HLA-DQ2 is more common and approximately 95 % of celiac patients have. The rest 
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have DQ8. These HLA-molecules are essentials in the progression of celiac disease, but 
not alone sufficient to induce the disease. The prevalence of celiac disease of first 
degree relatives is 1-18 % and the celiac disease concordance rate (75 %) in twins has 
long been cited as proof of the “genetic load” of the disease (Greco et al. 2002; Mäki 
and Collin, 1997) 
 
Gluten is the only required environmental factor shown to trigger celiac disease (Anand 
et al. 1978). Gluten is the general name for a mixture of proteins found in wheat, rye 
and barley: the ethanol-soluble prolamines and insoluble glutenins (Howdle 2006). 
Wheat´s prolamin is called gliadin, rye´s secalin and barley´s hordein. In celiac disease 
the gluten-derived glutamine-and proline-rich peptides, which are resistant to 
degradation by gastrointestinal proteases, induce both innate and adaptive immune 
responses (Shan et al. 2002). Some of these incompletely digested peptides can cross 
the epithelium and enter the lamina propria of the small intestine under certain 
conditions. It is thought that stress factors could lead to changes in intestinal 
permeability that allow the gluten peptides to enter the lamina propria (Aleadini and 
Green, 2005). For instance, gastrointestinal infections have been found trigger celiac 
disease (Stene et al. 2006). The innate immune response to gluten could also be a 
predecessor of mucosal changes that increase intestinal permeability. When gluten 
enters the gastrointestinal tract, it is only partially cut up by gastrointestinal enzymes 
leading to large peptides some of which are immunogenic to celiac disease patients 
(Shan et al. 2002).  
 
Activity of cells and mechanisms defending the host from infection by other organisms 
in an immediate and non-spesific manner is called innate immunity (Koning 2005). In 
genetically susceptible individuals incompletely digested gluten peptides evoke an 
innate immunity response presumably mediated by interleukin (IL) 15 in celiac disease 
(Maiuri et al. 2000). The innate response to the toxic gliadin peptides, especially p31-43 
peptide fragment, is mediated by the proinflammatory cytokine IL-15 and it is thought 
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to mediate most of the pathogenic alterations in the epithelium in celiac disease (Maiuri 
et al. 2000; Maiuri et al. 2003; Maiuri et al. 2005). IL-15 is found to be over-expressed 
in both the lamina propria and the intestinal epithelium in patients with active disease 
(Hue et al. 2004). It has also been shown that the epithelial cells are activated in the 
presence of an excess of IL-15 (Stepniak and Koning, 2006). 
 
IL-15 acts as a driving force in the complex expansion of intraepithelial T lymphocytes 
(IELs) (Mention et al. 2003; Meresse et al. 2009). It may be the main factor in the 
activation and selective expansion of IELs. Moreover, IL-15 can block TGF-β signaling 
and in that way enhance the activation of CD4+ T cells and IELs (Benahmed et al. 
2007). It has been found that overexpression of IL-15 in transgenic mice leads to  small 
bowel mucosal damage, similar to that seen in celiac disease (Ohta et al. 2002). 
Secretion of IL-15, which is evoked by gliadin peptides, eventually leads to epithelial 
cell death. That is thought to help the immunogenic gliadin peptides to enter the lamina 
propria (Hue et al. 2004; Lindfors et al. 2009). These peptides cross the epithelium by 
active transport through a transcellular endocytic pathway or passive paracellular 
transport. Also the upregulation of zonulin, a protein involved in the regulation of tight 
junctions, may lead to increased epithelial permeability in celiac disease (Fasano 2000). 
That would allow incompletely digested peptides to enter the lamina propria (Molberg 
et al. 1998). 
 
The adaptive immunity is based on the maturation cycle of T and B cells and 
particularly the toxic 33-mer peptide fragment p56-89 induce adaptive immunity 
response (Molberg et al. 1998; Shan et al. 2002; Maiuri et al. 2003). In celiac disease, it 
also involves activation of HLA-DQ2/HLA-DQ8 -positive small intestinal mucosal T-
cells. In the small-intestinal lamina propria gluten peptides are deamidated by TG2, 
which increases their affinity for the HLA-DQ peptide binding motif in antigen-
presenting cells (APCs) (Molberg et al. 1998; Sollid 2002). 
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The APCs present the deamidated gliadin peptides bound to DQ2 or DQ8 to CD4+ T 
cells which are activated and become pathogenic CD4+ cells (Sollid 2002). These 
inflammatory CD4+ T- cells also produce other proinflammatory cytokines and 
mediators such as tumor necrosis factor alpha (TNF-α). These are thought to induce 
secretion of TG2-targeted autoantibodies by mucosal B-cells. Plasma cells produce 
antibodies against both gluten peptides and TG2 (Jabri and Sollid, 2006). These 
antibodies activate monocytes, enhance epithelial permeability, weaken extracellular 
matrix, increase proliferation of fibroblasts and inhibit their motility and prevent 
angiogenesis (Halttunen and Mäki, 1999; Zanoni et al. 2006; Barone et al. 2007; 
Lindfors et al. 2009).  
 
Adaptive immunity involves also the humoral immune response: T cells induce B cells 
to activate to antibody-producing plasma cells (Sollid 2002).  The intestinal mucosa B-
cells mainly secrete a repertoire of IgA dimers, and in celiac disease production of 
antibodies is clearly gluten-dependent (Mäki 1995; Sollid 2002). It is suggested that  
IgA enhances the passage of gliadin peptides, p31–43 and p57–68, through epithelial 
cells (Rauhavirta et al. 2011). Also the basal media collected from cultures 
supplemented with untreated celiac patient IgA containing the translocated p57–68 
peptides, were able to induce proliferation of celiac patient T cells even without 
pretreatment with TG2.  Moreover, IgA increases the cross-linking activity of TG2 and 
inhibition of TG2 abolishes the enhanced transepithelial passage of gliadin peptides. 
These antibodies were able to increase epithelial cell permeability and   induce 
monocyte activation upon binding to Toll-like receptor 4 (Zanoni et al. 2006). In 
addition, also a variety of antibodies against own tissues, autoantibodies, are produced, 
for example reticulin, endomysium and TG2 antibodies.  DQ2 binding affinity, 
correlation of TG2 substrate specificity and T cell stimulatory potential of TG2-treated 
prolamins strongly suggests that peptide deamidation is caused by TG2, and that TG2 
may plays a significant role in the disease (Molberg et al. 1998).  
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In the early 1990s, Mäki suggested that in celiac disease autoantibodies could be 
generated in the hapten-carrier model and later TG2 was implicated as a major 
autoantigen in celiac disease (Mäki 1994; Dieterich et al. 1997). In addition to 
transamidase activity of TG2, it also contributed to the humoral response by forming 
hapten-carrier complexes in the form of covalent TG2-gluten peptide complexes and 
collagen-gluten peptide complexes. B cells stimulate TG2-specific antibodies through 
CD4+ helper cells. 
 
TG2-targeted autoantibodies are produced locally in the gut and these anti-TG2 
antibodies are found both in the circulation and deposited in the small-bowel mucosa 
below the basement membrane and around the blood vessels (Marzari et al. 2001; 
Korponay-Szabo et al. 2004; Kaukinen et al. 2005). In the blood, TG2 antibodies are 
currently being used as a diagnostic tool for the disease (Kaukinen et al. 2010). Within a 
year on a gluten-free diet circulating antibodies disappear, but the mucosal deposits 
vanish slower (Korponay-Szabo et al. 2004; Kaukinen et al. 2005).  Celiac disease-
specific autoantibodies have been likewise reported to induce neuronal cell apoptosis 
and induce ataxia-like symptoms to mice when injected into the central nervous system 
(Boscolo et al. 2007). It has also been shown that patients suffering from gluten ataxia, 
have TG2-targeted autoantibody deposits around blood vessels in the brain but also in 
the small intestinal mucosa (Hadjivassiliou et al. 2006).  
 
In some celiac disease patients there are also antibodies against other transglutaminase 
family members and variety of other autoantibodies against other “self-antigens” (Sardy 
et al. 2002; Alaedini et al. 2008; Hadjivassiliou et al. 2008). Desmin, zonulin, actin, 
collagen types I, III, V, VI, calreticulin, gangliosides, synapsin I and cardiolipin are 
potential autogens as well (Alaedini et al. 2008). 
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4.4 Angiogenesis in celiac disease 
 
The potential role of angiogenesis in the pathogenesis of celiac disease has not been 
totally resolved. In the textbook of Coeliac Disease, the mucosal vasculature of celiac 
and non-celiac patient was visualized by ink injections (Cooke and Holmes, 1984). It 
was discovered that the overall architecture of the small intestinal vasculature was 
altered but the most striking finding was the altered overall organisation of the 
vasculature and the absence of capillary tufts. Already in the 1970s, it was found that 
ingestion of gluten led to endothelial swelling in the small intestinal capillaries of celiac 
patients (Shiner et al. 1972; Shiner 1973). 
 
The mucosal vasculature in the small intestine of untreated celiac disease patients was 
altered as to overall organization as well as to the number and maturity of the vessels 
(Myrsky et al. 2009B). Interestingly, in patients on a gluten-free diet, the vasculature 
was normalized parallel to mucosal recovery. Ingestion of gluten lead to altered 
appearance of small-bowel mucosal microvasculature in celiac disease and thus the 
small-bowel mucosal vascular biology may well involved in the pathogenesis of celiac 
disease 
 
Antibodies targeting TG2 are present in a serum of celiac disease patient but they are 
also found bound to TG2 under the epithelial basement membrane and around 
capillaries in the small intestinal mucosa (Marzari et al. 2001; Korponay-Szabo et al. 
2004; Kaukinen et al. 2005). These autoantibodies disturb numerous steps of 
angiogenesis: endothelial sprouting and migration of vascular and endothelial 
mesenchymal cells (Myrsky et al. 2008). Moreover, the autoantibodies cause 
disorganization of the actin cytoskeleton in capillary cells that account most probably 
for the defective cellular migration. It was concluded that celiac disease-specific 
autoantibodies recognizing TG2 inhibit angiogenesis in vitro suggesting that this 
disturbance could lead in vivo to the disruption of the mucosal vasculature seen in celiac 
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disease patients on a gluten-containing diet (Myrsky et al. 2008). IgA derived from 
celiac disease patients on a gluten-containing diet binds to surface TG2 in vitro on 
endothelial and vascular mesenchymal cells. This binding can be inhibited by the 
removal of TG2 or by using celiac disease-specific autoantibodies targeting TG2.  
 
Celiac patient-derived monoclonal TG2-targeted antibodies inhibited endothelial tubule 
formation and enhanced the crosslinking activity of TG2 (Caja et al. 2010). When this 
enzymatic activity was inhibited by site-directed irreversible TG2 inhibitors in the 
presence of autoantibodies, in vitro angiogenesis returned to the control level. A 
Significant negative correlation between endothelial cell angiogenesis and TG2 activity 
was found and suggested that the anti-angiogenic effects of celiac patient-derived TG2-
targeted autoantibodies are exerted by enhanced enzymatic activity of TG2. 
 
Autoantibodies found in celiac disease increase endothelial permeability for 
macromolecules. These autoantibodies also enhance the binding of lymphocytes to the 
endothelium and their transendothelial migration (Myrsky et al. 2009A). It was also 
demonstrated that these effects are mediated by increased activities of TG2 and RhoA. 
Since the small bowel mucosal endothelium serves as a ‘‘gatekeeper’’ in inflammatory 
processes, the disease-specific autoantibodies, targeted against TG2, could contribute to 
the pathogenic cascade of celiac disease by increasing blood vessel permeability. 
 
 
 
 
5 CONCLUSIONS 
 
 
Celiac disease may in itself increase the risk for cancers of the upper-gastrointestinal 
tract through the activation of T-cells that release proinflammatory cytokines (Askling et 
al. 2002). The mechanisms behind these malignancies are not fully known, but among 
other things following have been presented: chronic inflammation, release of 
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proinflammatory cytokines, increased intestinal permeability of environmental 
carcinogens and immune surveillance problems (Green et al. 2003). TG2 has an 
important role in celiac disease and it is crucial in restoring the normal homeostasis 
(Kumar et al. 2010). Interestingly TG2 seems to have both proapoptotic and anti-
apoptotic effects on cancer cells (Lee et al. 2004; Mann et al. 2006). The relevance of 
TG2 to cancer biology  depend on the type of cancer, the cancer cell type, the location 
of the cancer, the stage of the cancer and more importantly on the localization of TG2 
within or outside the cell (Siegel and Khosla, 2007). Nuclear, cytosolic, membranous or 
extracellular TG2 seem to affect cell growth, survival or invasion in totally different 
ways.  
 
Recent studies suggest a direct significance to the role of TG2 in angiogenesis which is 
also important in tumorigenesis.  It is suggested that the anti-angiogenic effects of celiac 
patient-derived TG2-targeted autoantibodies are exerted by enhanced enzymatic activity 
of TG2 (Caja et al. 2010). Celiac disease -specific TG2 -targeted autoantibodies disturb 
several steps of angiogenesis: endothelial sprouting and the migration of both 
endothelial and vascular mesenchymal cells and cause disorganization of the actin 
cytoskeleton in both capillary cell types that account most probably for the defective 
cellular migration (Myrsky et al. 2008). Celiac disease autoantibodies recognizing TG2 
inhibit angiogenesis in vitro, and when this activity was inhibited by using TG2 
inhibitors in the presence of autoantibodies in vitro, angiogenesis was reverted to the 
control level (Caja et al. 2010). 
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EXPERIMENTAL PART 
 
 
 
1 INTRODUCTION 
 
 
 
 
Malignancies are the most severe complications associated with celiac disease and 
celiac disease patients have increased cancer risk, especially lymphomas are common. 
Gluten-free diet is beneficial to the symptoms of celiac disease, including malignancies. 
Population screening of EmA/TG2 antibodies in the follow-up of two decades revealed 
that the overall risk of malignancy was not increased among antibody-positive cases 
(Lohi et al. 2009). As aforesaid celiac disease patients have TG2 antibodies in serum 
and as deposits. TG2 is involved in tumorigenesis and angiogenesis which supports 
tumorigenesis. Celiac disease TG2 autoantibodies may inhibit angiogenesis. Based on 
the above it, is intriguing to think that celiac disease autoantibodies may affect 
tumorigenesis.   
 
 
2 AIMS OF THE PILOT STUDY 
 
 
The aims of this pilot study were to establish whether celiac disease TG2 autoantibodies 
affect in vivo tumorigenesis and try to clarify the mechanism behind the phenomenon. 
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3 MATERIALS AND METHODS 
 
 
3.1 Cell lines and cultures 
 
OE-19 (human adenocarcinoma of gastric cardia/esophageal gastric junction of a 72- 
year-old male patient), MKN-7 (human stomach tubular adenocarcinoma), and SNU-
216 (human gastric cancer) cell lines were used in the studies.  All the cells were kind 
gifts from Professor Jorma Isola and Mark Barok (MD, PhD), Institute of Biosciences 
and Medical Technology. Cells were cultured in RPMI 1640 cell medium (GIBCO 
Invitrogen, Paisley, UK) containing  200 mM L-glutamine [GIBCO Invitrogen], 10 % 
Fetal Bovine serum, FBS [GIBCO Invitrogen] and 50 IU/ml penicillin-streptomycin 
[Invitrogen]). Media were changed two-three times a week. All cultures were 
maintained in a humidified environment at 37 ºC with 5 % CO2. Cells were tested for 
mycoplasma contamination using the Mycoplasma Detection Kit (VenorGeM, Minerva 
Biolabs GmbH, Berlin, Germany). Cell count and viability were determined using 0,4 
% trypan blue solution (Sigma Aldrich, St. Louis, MO, USA). Cells were detached from 
the bottom of bottle by using 0,25 % trypsin-EDTA solution (Sigma Aldrich, St. Louis,  
MO, USA).  
 
 
3.2 Mini- autoantibodies and TG2 inhibitor R281 
 
Monoclonal miniantibodies were produced by recombination technology. The celiac 
patient-derived anti-TG2-specific antibody fragment, clone 2.8 (referred as mini 2.8) 
and irrelevant control antibody clone 6.2 (referred as mini 6.2) targeted against E. coli 
protein M5 were a kind gifts from Professors Roberto Marzari (University of Trieste, 
Italy) and Daniele Sblattero (University of Eastern Piedmont, Italy). Antibodies were 
generated as miniantibodies essentially as previously described in Chinese hamster 
ovary cells (Di Niro et al. 2007). The site-directed irreversible TG2 inhibitor R281 was 
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a kind gift from Professor Martin Griffin (Aston University, United Kingdom) (Griffin 
et al. 2008).  
 
 
3.3 In vitro invasion assay 
 
Polycarbonate membranes of cell culture inserts (Millicell®, pore size 8μm, Millipore, 
Carrigtwomil, Co Cork, Ireland) were coated with 100 µl of 1 mg/ml matrigel 
(Matrigel, Phenol Red free, 9.8 mg/ml, BD Biosciences, Bedford, MA, USA) and 
placed in wells of 24 well-plate (NunclonTM Δ Surface, Nunc A/S, Roskilde, Denmark).  
After four hours of incubation, 80 000 OE-19 cells per well were seeded in the upper 
chamber of the invasion plate in serum free media (SFM= RPMI1640, penicillin and L-
glutamine [GIBCO, Invitrogen]) in the presence or absence (see Table 1) of 
miniautoantibodies 2.8/6.2 (concentration 1 μg/ml). Some well were administered with 
TG2-inhibitor R281 (concentration 500 nM). Normal media with 10 % FBS and an 
equimolar concentration of antibody or controls were pipeted in the lower chamber (see 
Figure 1). The invasion plate was incubated at 37 ˚C and 5 % CO2 for 20 hours. Cells 
that have not invaded were removed and invaded cells were fixed with 4 % 
paraformaldehyde (PFA) (Sigma Chemical, St. Louis, MO, USA) for 10 minutes at 
room temperature and then washed with PBS.  
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Figure 1. Schematic presentation of the in vitro invasion assay. Polycarbonate 
membranes of cell culture inserts were coated with 100 μl of 1 mg/ml matrigel and 
placed in wells of 24 well-plate.  After four hours of incubation 80 000 cells per well 
were seeded in the upper chamber of the invasion plate in serum free media in the 
presence or absence of miniautoantibodies 2.8/6.2 (concentration 1 μg/ml) and with or 
without transglutaminase 2 (TG2)-inhibitor R281 (concentration 500 nM). Normal 
media with 10 % fetal bovine serum (FBS) and an equimolar concentration of antibody 
or controls were pipeted in the lower chamber. For 20 hours invasion plate was 
incubated at 37 ˚C and 5 % CO2. 
 
Table 1. Different variations of miniantibodies and TG2 inhibitor R281 in in vitro 
invasion assay.  
 
1. Matrigel + medium + cells 
2. Matrigel with 6.2 + medium + cells 
3. Matrigel with 2.8 + medium + cells 
4. Matrigel with R281 + medium + cells 
5. Matrigel with R281 and 6.2 + medium+cells 
6. Matrigel with R281 and 2.8+medium+ cells 
7. Matrigel with 6.2 + medium with 6.2 + cells  
8. Matrigel with 2.8 + medium with 2.8 + cells 
9. Matrigel with 6.2 and R281 + medium with 6.2 + cells 
10. Matrigel with 2.8 and R281 + medium with 2.8 + cells 
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The invaded cells were stained with crystal violet (~ 150 µl/insert, 5 µl crystal violet in 
one ml PBS) for 60 minutes, then membranes were washed, severed, mounted with 
Vectamount AQ (Vector Laboratories Inc., Burlingame, CA, USA), viewed with 
Olympus BX60 microscope and analysed with Cell^D software program. Cells invaded 
to membrane were calculated from rectangle area cross the well from all membranes 
and approximately 12 fields per membrane with 10x objective. All experiments were 
made in duplicates. 
 
 
3.4 TG2 expression and TG activity stainings for cancer cells 
 
Both TG2 expression and activity stainings were performed to all three cancer cell lines 
(OE-19, SNU-216 and MKN-7). We used CUB7402 (mouse monoclonal, Labvision, 
NeoMarkers, Fremont, USA) and A014 (rabbit polyclonal,1:50 in PBS, Zedira, 
Darmstadt, Germany) antibodies, both at dilution of 1:200 for TG2 expression staining 
and 0,2 mM EZ-Link® Pentylamine-Biotin (5-biotinamidopentylamine, Thermo 
Scientific, Rockford, IL, USA) for TG activity staining. Both confluent and non-
confluent cultures as well as permeabilized and non-permeabilized cells were stained.  
 
For TG2 expression staining, the cells were first fixed with PFA for 10 minutes at room 
temperature. After washings with PBS a subset of cultures were permeabilized with  0,1 
% Triton X-100 (Sigma-Aldrich) in PBS for 10 minutes and washed with PBS. 
Thereafter the cells were incubated in the presence of primary TG2 antibodies 
CUB7402 (Labvision, NeoMarkers) or A014 (Zedira) diluted in 1:200 in 0,5 % BSA-
PBS. After washes with PBS cells were blocked in normal goat serum (Vectorlabs) 
diluted 1:20 in 5 % BSA-PBS for 30 minutes to one hour and washed with PBS. 
Subsequently the cells were incubated with secondary antibodies as follows: A014 
treated cells with Alexa Fluor 568 goat α-rabbit IgG (1:2000, Invitrogen, Eugene, 
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Oregon, USA) and CUB7402 treated cells with Alexa Fluor 568 goat α-mouse IgG 
(1:2000, Invitrogen, Eugene, Oregon, USA) for 30 to 45 minutes. Secondary antibodies 
were diluted in 0,5 % BSA-PBS. After incubation cells were washed with PBS and 
mounted with Vectashield mounting medium with DAPI (Vector Laboratories Inc, 
Burlingame, CA, USA). After staining slides were observed with Olympus BX60 and 
representative photos were taken. 
 
TG activity staining was performed similarly with few exceptions: primary antibodies 
were replaced by 0,2 mM EZ-Link® Pentylamine-Biotin (Thermo Scientific) for 45 
minutes at 37 ºC and washed with PBS and fixed with PFA (Sigma Chemical) for 10 
minutes in cold after primary antibody incubation. EZ-Link® Pentylamine-Biotin 
followed by an incubation in the presence of  polyclonal rabbit α-mouse tetramethyl 
rhodamine isothiocyanate (TRITC)-labeled streptavidin (1:200, KPL, Gaithersburg MP, 
USA). 
 
 
3.5 Western blot analysis 
 
To compare the amount of TG2 protein and TG activity in OE-19, SNU-216 and MKN-
7 gastric cancer cell lines western blot analysis (WB) was performed. Cells were 
cultured in humified environment at 37 ºC with 5 % CO2. For the TG activity 
determination, cells were incubated with 2 mM monodansylcadaverine (Sigma Aldrich, 
St. Louis, MO, USA) for 30 minutes and washed extensively with PBS. Thereafter the 
cells were trypsinized with 0,25 % trypsine-EDTA (Sigma Aldrich) and resuspended in 
medium. Cell lysates were prepared for sodium dodecyl sulphate polyacrylamide-gel 
electrophoresis (SDS-PAGE) by diluting 1:1 cell suspension and Laemmli-buffer (see 
Appendix 1) and heating samples for five minutes. Finally cell lysates were frozen at -
20 ºC.  Samples were run on 10 % SDS-PAGE gels (see Appendix 1) using Bio-Rad 
Mini-Protean Tetra Cell System (Biorad Laboratories, Espoo Finland) in SDS-running 
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buffer (see Appendix 1). As a marker we used PageRuler
™ 
Plus Prestained Protein 
Ladder  (Fermentas). Samples were run approximately an hour with 100-150 volts.  
 
Samples were transferred from gel to nitrocellulose membrane (Hybond C-extra, 
Amersham Biosciences Ltd, Little Chalfont, UK) with blotting device (Biometra 
Fastblot B43, Göttingen, Germany) for 45 minutes with 35 volts. After transfer 
nitrocellulose membrane was blocked with non-fat milk solution (non-fat milk powder 5 
% , Valio, Finland). After blocking nitrocellulose membrane was washed with PBS and 
then incubated with primary antibodies: mouse anti-γ-tubulin (Sigma, Saint Louis, 
Missouri, USA), rabbit α-dansyl IgG (Molecular Probes, Eugene, OR, USA) or 
CUB7402 mouse monoclonal (Labvision, NeoMarkers, Fremont, USA) over night at 4 
˚C. 
 
After primary antibody treatments nitrocellulose membrane was washed three times 
with PBS in a shaker and then nitrocellulose membrane was incubated with horseradish 
peroxidase-conjugated secondary antibodies: polyclonal rabbit α-mouse 
immunoglobuline (Dako Denmark A/S, Glostrup, Denmark) for CUB7402 and γ-
tubulin, and polyclonal swine α-rabbit immunoglobuline (Dako Denmark A/S, Glostrup, 
Denmark) for α-dansyl rabbit IgG (dilution 1:1000 in 5 % milk and 0,05 % Tween 20 
[MP Biomedicals, LLC, Solon, OH, USA] in PBS) for one hour in a shaker. Then 
nitrocellulose membranes were washed with PBS at room temperature. 
 
Protein bands were visualised by adding photo development solution (ECL Plus, 
Western blotting detection system, Amerham, UK) to the membrane and incubated for 
five minutes. Autoradiography film (Super RX, Fujifilm Corporation, Tokyo, Japan) 
was exposed to the membrane and developer (Konica SRX-101A, Konica Corporation, 
Taiwan). Pictures were analysed and TG2 expression quantified with Kodak 1D image 
analysis, software-program (Kodak). TG2 expression and TG activity results were 
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normalized by dividing them with the results of γ-tubulin densities. 
 
3.6 Tumor induction in severe combined immunodefiency mice  
 
For in vivo studies, 4-week-old female SCID-mice (C.B-17/IcrHan™Hsd-Prkdcscid, 
Harlan, UK) were ordered from Harlan and housed at 22 ºC, with water and food freely 
available and with a 12-hour light/dark cycle. The animals were cared for and used in 
accordance with the regulations in Finland (62/2006 and 36/EEo/2006) and the 
European Union (86/609/EC), and the protocol was approved by the the National 
Animal Ethics Committee in Finland (licence ESAVI-2010-06224/Ym-23). SCID-mice 
lack T- and B- cells and therefore are unable to elicit an immune response against 
foreign material.  
 
Mice were randomly separated into treatment groups (two animals per group). Tumor 
cells were incubated with autoantibodies for two hours just before injections in 
incubator at 37 ˚C (Figure 2). OE-19 tumor cells (five million cells per animal) 
resuspended in medium (200 µl) were injected to mice flank subcutaneously with a 22-
gauge needle. Celiac disease autoantibodies (mini 2.8) were injected to two of mice, 
non-celiac autoantibodies (mini 6.2) to two and the last two, control mice, were injected 
with PBS. Autoantibodies (2.8 or 6.2, concentration 0,2 mg/ml) or PBS were injected 
twice a week with a 27-gauge needle subcutaneously on tumors. During the experiment 
the mice were weighted and the tumor size was measured two/three times per week. To 
estimate the volumes of tumors the following formula was used: π/6 * L* W* H, where 
L is length, W is width and H is height (Tomayko and Reynolds, 1989). In Tomayko´s 
and Reynolds´article they validated different formulas which have been used to estimate 
tumor volumes. Formula π/6 * L* W* H was shown to be the most accurate formula 
when estimating tumor volumes. 
 
Experiment lasted for four weeks after which the mice were sacrificed (Figure 2). Mice 
were anaesthetized with Dormitor®: Ketalar®: 0,9 % NaCl dilution (1:2:7). After 
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couple of minutes cardiac puncture was performed and cardiac blood collected into 
heparin plasma tubes (Venosafe® Plastic Tubes, Terumo, Europe) to determine TG2-
antibodies (IgGs) from sera. Tumors were excised and cut in half, the other half was 
formaline-fixed (see Appendix 1) for histopathology and the other half was frozen. 
Frozen sections (5 μm) and parafine sections (3 μm and 9 μm) were cut from the 
samples.  
 
 
Figure 2. Schematic presentation of tumor xenograft model in severe combined 
immunodeficient (SCID) mice. Human oesophageal carcinoma (OE-19) cancer cells 
were incubated with celiacs TG2 miniautoantibody (mini 2.8), non-celiac 
miniautoantibody (mini 6.2) or PBS before cancer cells were injected to mice flank 
Injection of OE-19  
tumoral cells, s.c.  
(5 million cells in 200μl) 
to SCID mice 
2 injections of Celiac disease or 
control monoclonal antibodies/ week 
 intratumoral concentration 0,2 mg/ml 
Measure of tumor growth  
and weightening of the mice  
weekly 
Anestesia, blood sampling,  
mice sacrifying and tumor  
removing 
28 days
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subcutaneously (s.c.). 
 
 
 
3.7 Immunohistochemical stainings for tissue sections 
 
3.7.1 Hematoxylin-eosin staining 
 
Hematoxylin-eosin (HE)-staining was performed to study the morphology of the tumors 
and to determine the portion of the necrotic areas from entire tumor areas. First paraffin 
sections were deparafinated in xylene followed by descending alcohol series. After 
deparafination slides were in Harris Hematoxyline solution (Merck KGaA, Darmstadt, 
Germany) for 10 minutes and thereafter in running water for seven minutes. Then slides 
were rinsed quickly in acid-alcohol and in running water for seven minutes. 
Subsequently the slides were stained with Eosin Y (Riedel-de Haën, Seelze, Germany) 
for 2,5 minutes, and dehydrated in alcohol and xylene. Finally slides were mounted with 
Vectamount mounting medium (Vector Laboratories Inc., Burlingame, CA, USA). After 
staining slides were observed with Olympus BX60, representative photos were taken 
and necrotic areas determined. 
 
 
3.7.2 Ki-67 proliferation staining 
 
Ki-67 staining was performed to examine the proliferation in the tumors in frozen 
sections. First, frozen sections were airdryed for 20-30 minutes. Then sections were 
fixed in acetone-alcohol solution for three minutes and airdryed. Dryed slides were 
washed in PBS three times, incubated in normal serum goat (Vectorlabs, dilution 1:20 in 
5 % milk powder 5 % BSA destilled water) for 30 minutes and thereafter with primary 
antibody Ki-67 (clone SP6, Novus Biologicals LLC, Littleton, Colorado, USA) using 
dilution of 1:100 in 0,1 % BSA-PBS for one hour at room temperature. Subsequently 
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the slides were washed with PBS and incubated with secondary biotinylated α-rabbit 
antibody (Vector Laboratories, Burlingame, dilution 1:100 in 5 % normal serum goat in 
PBS) for 30-60 minutes. After washes in PBS, the slides were incubated in 3 % H202 in 
PBS. This was followed by washing in PBS and incubation in ABC solution (Vectastain 
Elite ABC kit, Vector Laboratories, Burlingame, California, USA, see Appendix 1) for 
30 minutes. After washings slides were incubated in AEC –solution (see Appendix 1) 
for 30 minutes and thereafter washed in running water. This was followed by 
counterstaining with Harris-Hematoxyline (Merck KgaA). Finally the slides were 
washed, air-dryed for 15 minutes and mounted with Vectamount AQ (Vector 
Laboratories). After staining slides were observed with Olympus BX60 and 
representative photos were taken to determine proliferating cells. 
 
3.7.3 CD34 blood vessel staining  
 
The CD34 staining was used to quantify blood vessel areas from tumor sections.  Tumor 
xenograft paraffin sections were stained for CD34 using the Vectastain Elite ABC kit, 
similarly to Ki-67 staining. First sections were deparafinated as previously described 
and citrate buffer (see Appendix 1) was used for antigen retrieval. Anti-mouse CD34 
antibody (clone MEC 14.7, Novus Biologicals LLC, Littleton, Colorado, USA, diluted 
1:50 in PBS) and biotinylated anti-rat secondary antibody (Vectorlabs, dilution 1:100) 
were used. Before mounting slides were counterstained with Harris-hematoxylin 
(Merck KGaA). Then the cells were mounted with Vectamount AQ (Vector 
Laboratories) and observed with Olympus BX60. For quantification 15 pictures per 
mouse were taken and pictures were chosen so that the areas containing the most of 
blood vessels were taken into account. Blood vessel areas (AU) were quantified using 
Image J software and statistical analyses were performed to blood vessel area CD-34 
staining using the non-parametric two-tailed Mann-Whitney U-test in PASW statistic 18 
software. The data were presented as mean standard error of the mean (s.e.m.) and a P-
value < 0,05 was considered significant. 
43 
 
 
 
3.7.4 Masson´s trichrome staining  
 
Masson´s trichrome staining was performed to study the morphology of the tumors and 
the amount of collagen in tumors. First paraffin-embedded sections were deparafinated 
as previously described and first stained with Weigert ironhematoxyline (see Appendix 
1) for one to two minutes. Then slides were rinsed in running water for 10 minutes, 
stained with Ponceau-Säurefucksin-Azophlozin (see Appendix 1) for five minutes and 
then rinsed with 1 % acetic acid. This was followed by staining with phosphomolybdic 
acid orange (see Appendix 1) for two minutes, quick rinse with 1 % acetic acid and 
staining with Lichtgrun (see Appendix 1) for 4,5 minutes and again rinse with acetic 
acid for five minutes. Finally slides were dehydrated with ascendant alcohol series and 
xylene. Finally sections were mounted with Vectashield mounting medium (Vector H-
1000, Vector Laboratories Inc.). After staining slides were observed with Olympus 
BX60, representative photos were taken and the amount of collagen visually examined 
with Image J software. 
 
 
3.7.5 TG2 expression and TG activity staining for tissues with A014 and EZ-Link® 
Pentylamine-Biotin  
 
TG2-expression and TG activity stainings were also performed to frozen tumor sections 
to compare the TG2-expression and TG activity results from different treatment groups. 
This was done essentially as described in 3.4 TG2 expression and TG activity stainings 
for cancer cells except that only A014 (Zedira) was used for TG2 expressions and at the 
beginning frozen section slides were air-dryed at room temperature for 20 minutes.  
After primary antibody incubation EZ-Link® Pentylamine-Biotin treated sections were 
acetone fixed for 10 minutes at room temperature, air-dryed fast and washed with PBS. 
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Then all the sections from both stainings were blocked with 5 % normal serum horse 
(Vectorlabs) in PBS and washed with PBS. Sections for TG2 expression staining were 
incubated with secondary antibody TRITC (swine α-rabbit 1:100 in PBS, Dako A/S) 
and sections for TG activity staining were incubated with TRITC-labeled streptavidin 
(1:200 in PBS, KPL) for 30 minutes at room temperature.  
 
 
3.7.6 Cross-linking staining 
 
Cross-linking staining was performed to analyze TG-catalysed cross-links there are in 
paraffin-embedded tumor sections. At first sections were deparafinated and antigen 
retrieval was performed as previously described. After microwaving sections were 
washed with PBS for two minutes three times each and blocked with normal serum goat 
(1:20, Vectorlabs) in 5 % milk PBS for 20 minutes at room temperature as previously 
described. Then slides were incubated with monoclonal antibody to N(γ-L-glutamyl)-L-
lysine isopeptide (mab 0012, Covalab, Lyon, France) with dilution 1:50  in milk PBS 
for one hour and washed with PBS. Secondary incubation was done with biotinylated α-
mouse IgG antibody (Vectastain, Vector laboratories, 1:100) for 30 minutes in 0,1 % 
BSA-PBS, washed with PBS and then incubated in H2O2 in PBS for 30 minutes.  This 
was followed by washes with PBS and incubation in ABC-solution (Vectastain Elite 
ABC kit, Vector Laboratories) for 30 minutes. Subsequently the slides were incubated 
with AEC-solution (see Appendix 1) for 30 minutes. Slides were again washed with 
running water for five minutes, stained with Harris-Hematoxyline (Merck KgaA) for 1,5 
minutes, washed with running water for three minutes and air-dryed for 15 minutes. 
Finally slides were mounted with Vectamount AQ (Vector Laboratories). After staining 
slides were observed with Olympus BX60 and representative photos were taken.  
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 4 RESULTS AND DISCUSSION 
  
4.1 In vitro experiments 
 
4.1.1 Invasion assay results 
 
In all different versions there were less cells in mini 2.8 treated membranes than in mini 
6.2 treated ones and control membranes (see Figure 3.). Mini 2.8 inhibited cells 
migration to membranes. It seems that TG2-inhibitor R281 worked well preventing TG2 
because there were clearly less cells in R281 treated membranes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Number of invaded cells in in vitro invasion assay. 
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When mini 2.8 was administered to matrigel cell invasion was decreased. This 
decreased was further enhanced when mini 2.8 was also present in the medium. The 
control antibody 6.2 had no major effect on invasion. Inhibition of TG2 activity by itself 
also inhibited invasion. 
 
 
4.1.2 TG2 expression and TG activity in cell lines 
 
WB analyses and immunofluoresence stainings showed that there is more TG2 
expression in the control cell lines SNU-216 and MKN-7 and hardly any TG2 
expression in OE-19 cell line (Figure 4A). Interestingly, the TG activity is on the same 
level in OE-19 cell line than in control cell lines (Figure 4B). 
 
 
 
 A.      B.  
 
Figure 4. A representative western blotting showing TG2 expression (4A) and TG 
activity (4B) in three cancer cell lines (SNU-216, MKN-7 and OE-19).  
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Figure 5. Representative pictures taken from immunofluoresence staining for 
transglutaminase 2 (TG2). There were hardly any TG2 expression in C) human 
oesophageal carcinoma (OE-19) cell line compared to other two gastric carsinoma cell 
lines A) human gastric cancer cell line (SNU-216) and B) human gastric 
adenocarcinoma cell line (MKN-7). There are permeabilized, non-confluent cells from 
all cell lines. Pictures are taken with 100x objective. 
 
 
These TG2 expression and activity results were parallel with WB results (see Figure 5). 
In OE-19 cells there is hardly any TG2 expression. There were no big differences 
compared confluent to non-confluent, but in permeabilized cells there is slightly more 
TG2 than non-permeabilized cells. Activity stainings were parallel to expression 
stainings but the differences between cell lines were even less. 
 
SNU-216 and MKN-7 cells express clearly TG2 (like in WB) but SNU-216 cells 
express more strongly than MKN-7. Immunofluoresence staining revealed that TG2 was 
not present on cell surface neither inside the cell in OE-19 cells. 
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4.2 In vivo experiments 
 
4.2.1 Tumor growth 
 
Tumor volumes were estimated two-three times per week using formula: π/6 * L* W* 
H, where L is length, W is width and H is height. After two weeks, the volumes started 
to  increase and PBS and mini 6.2 mice tumor volumes increased faster than tumor 
volumes of mini 2.8 (Figure 6). When mice were sacrified and tumors excised tumor 
volumes could be measured precisely, the tumor volumes of mini 2.8 group were almost 
1000 mm3 less than volumes of control groups. In addition the tumor mass results were 
parellel to volume results (Figure 7 and Figure 8). As to the mass results, the difference 
in the control groups were quite big, but in mini 2.8 group tumor masses were almost 
same. However, differences in volume results in all the groups were large. 
 
Figure 6. Mean tumor volumes of each treatment group. 
49 
 
 
 
Figure 7. Tumor masses as determined after tumor excision.  
 
 
 
 
Figure 8. Picture of tumors formed by human oesophageal carcinoma (OE-19)  cancer 
cell line in severe combined immunodefiency (SCID) mice. 
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4.2.2 Immunohistochemical stainings 
 
 
Hematoxylin-eosin (HE)-staining was done to study the morphology of the tumors 
(Figure 9) and necrotic areas were quantified as percentage of the entire tumor area. 
Figures from HE-stainings were used for quantification (Figure 10). The amount of 
necrotic areas in the tumors of mice from mini 2.8 group was almost the same, but in 
the control groups differences were bigger. The tumors of the mini 2.8 group had less 
necrotic area, but the result may be derived from the size of the tumor: the bigger the 
tumor is, the more there is necrotic area. 
 
 
 
 
Figure 9. Representative photos of hematoxylin-eosin (HE)-stainings of tumors. (A. 
PBS, B. mini 6.2, C. mini 2.8). Boundaries of the tumors are shown by darked lines. 
Pictures taken with 10X objective. 
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Figure 10.  The percentage of necrotic area of tumors in different treatment groups. 
 
 
 
Ki-67 staining was performed to examine the proliferation in the tumors, because the 
fraction of Ki-67-positive tumor cells is often correlated with the clinical course of 
cancer. There were no differences even if proliferating cells were quantified by using 
Image J software (Figure 11).   
 
Figure 11. Representative picture of Ki-67 staining of tumors (A. PBS, B. mini 6.2, C. 
mini 2.8). Pictures are taken with 10X objective. 
 
52 
 
 
Blood vessel area was quantified from CD34 stainings (Figure 12). Blood vessel area 
was significantly smaller in the tumors of mice from mini 2.8 group compared to 
control groups (Figure 13). Blood vessel areas were quantified using Image J software. 
Statistical analysis was performed to blood vessel area CD-34 staining using the non-
parametric two-tailed Mann-Whitney U-test. The data are presented as mean standard 
error of the mean (s.e.m.). When comparing blood vessel area differencies between mini 
2.8 to mini 6.2 and PBS group, the p-values was 0,019 (mini 2.8-mini 6.2) and 0,038 
(mini 2.8- PBS). Both these p-values are considered as significant. Whereas comparing 
mini 6.2 to PBS the difference between these control groups was no significant (NS).  
 
Figure 12. Representative photos of CD34 staining (A. PBS, B. mini 6.2 C. mini 2.8) 
are taken with 10X objective. 
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Figure 13. Quantification of blood vessels in tumors of PBS, mini 6.2 and mini 2.8 in 
arbitrary units (AU). The data are presented as mean and bars represent standard error 
of the mean (s.e.m.). P-value < 0,05 was considered significant. 
 
 
Masson´s trichrome staining was done to study the amount of collagen in tumors, which 
could be seen as blue/green in pictures (Figure 14). Visually examined there seemed to 
be more collagen in mini 2.8 compared to control groups. 
 
Figure 14. Masson´s trichrome staining of A. PBS, B. mini 6.2, C. mini 2.8 sections. 
Blue/green indicates collagen in tumors, nuclei are seen as black, cytoplasm as fire 
brick, erytrocytes as orange-red and, fibrin as a red. Visually examined there were more 
collagen in mini 2.8 compared to control groups. Photos taken with 10X objective. 
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After stainings the TG2 expression (Figure 15) and TG activity were quantified using 
Image J software. There were no significant differences between the groups either TG2 
expression or TG activity in stainings. 
 
 
Figure 15. Representative photos of TG2 expression staining on tissue sections (A. PBS, 
B. mini 6.2 and C. mini 2.8). Photos are taken with 10X objective. 
 
 
Cross-linking staining was also performed to see how much TG2 induced x-links there 
are in the tumor. The results were parallel with TG2 activity staining for the sections. 
All the different groups looked almost alike. 
 
 
4.2.8 Factors affecting in vivo results 
 
There were big differences in the consistencies of the tumors; one of the two tumors 
was soft and fluffy and the other ones were solid. When cutting sections from paraffin 
blocks, sections from these fluffy tumors were crushed and stainings with these crushed 
sections were challenging. Also the mice handler who gave the tumor cell injections 
should have been same person during, the cause of the expression because injector 
might have had influence how tumor cells were invaded and how near the skin cells 
were injected. 
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4.3 General discussion 
 
The results presented here suggest that celiac disease antibodies decreased tumor 
growth, but tumors in this experiment did not metastasize so that this aspect could not 
be addressed. As the OE-19 cell line used in the xenograft-experiments express little 
TG2, the antitumorigenic effect is likely caused by the host. This presumption is also 
supported by the fact that the angiogenic area was diminished in the tumors treated with 
celiac patient TG2-autoantibody 2.8. In the xenograft model, the tumor vasculature is 
made up of mouse cells. Moreover, mini 2.8 inhibited in vitro invasion of OE-19 cells in 
matrigel, and therefore the effect may come through the modulation of matrix. 
Collectively it could be speculated that the anti-tumorigenic effects of mini 2.8 are 
mediated by modulation of the extracellular matrix which leads to immunization of 
cancer cells and inhibition of vascularisation of the tumor. However, the proving this 
hypothesis certainly requires further studies. If a large scale experiment gives similar 
results, it might give a hint what happens in celiac disease patients and about the role of 
TG2. Also it would be interesting to know what would happen in the cancer cell lines 
that express a lot of TG2. 
 
 
5 CONCLUSIONS 
 
 
Our results suggest that celiac disease anti-TG2-autoantibodies inhibit tumor growth, 
but the number of animals (six) is low. Further test with larger number of animals is 
needed.  
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APPENDIX 1 
 
 
Solutions and reagents 
 
 
 
Laemmli-buffer 
 
Add beta-mercaptoethanol (2-mercaptoethanol) at a final concentration of 2.5 to 5.0 %. 
(47,5 μl mercaptoethanol to 452,5 μl 2x SDS laemmli-buffer ) and then mix with cell 
suspension 1:1. 
 
 
SDS-PAGE - upper gel 
 
H2O     2,7  ml 
30 % acrylamide    0,67 ml 
1,0 M Tris-HCl (pH 6,8)  0,5 ml 
SDS (10 %)    0,04 ml 
APS (10 %)    0,04 ml 
TEMED     0,004 ml 
 
 
2x SDS sample buffer 
 
0,5 M Tris-HCl, pH 6.8  2,5 ml 
Glycerol    2 ml 
10 % (w/v) SDS   4 ml 
0,1 % (w/v) bromophenol blue 0,5 ml 
H2O    ad 10 ml 
 
 
Solution for Tris/glysine SDS-PAGE gel electrophoresis (10 %) 
 
H2O   7,9 ml 
30 % Acrylamide  6,7 ml 
1,5 M Tris (pH 8.8) 5,0 ml 
10 % SDS  0,2 ml 
10 % APS  0,2 ml 
TEMED  0,008 ml 
 
 
  
 
 
5x running buffer  600 ml 
 
Trizma base  9 g  
Glysine  43,2 g  
SDS   3 g 
H2O   ad 600 ml 
 
 
1x transfer buffer 1000 ml 
 
Trizma base 1,256 g 
Glysine 7,2 g 
Methanol 200 ml 
H2O   800 ml 
 
 
Neutral formaline 
 
Formaldehyde 37 %  10 ml 
H2O   90 ml 
NaH2PO4·H2O  0,4 g 
 
 
10x Phosphate buffered saline (PBS) 
 
NaCl  8 g 
KCl  0,2 g 
Na2HPO4 1,44 g 
KH2PO4 0,24 g 
H2O   ad 800 ml 
 
 
ABC-solution 
 
One drop A-solution (Vecstain Elite ABC, Vector laboratories) and one drop B-solution 
(Vecstain Elite ABC, Vector laboratories) in 2,5 ml PBS. Do at least 30 minutes before 
using. 
 
 
AEC-formamide stock solution 
 
40 mg 3-amino-9-ethylcarbazole 
10 ml N,N-dimethylformamide 
 
  
 
 
 
AEC-solution (for 8 slides) 
 
Acetate buffer 0,1M 1120 µl  
AEC formanide 80 µl  
3 % H2O2   in H2O 12 µl  
 
 
Citrate buffer 10 mM 
 
Citrate buffer 0,1 M 30 ml 
H2O     ad 300 ml 
 
 
Weigert´s ironhematoxyline: 
 
Solution A: 1g hematoxyline and 100 ml 96 % alcohol 
Solution B: 450 ml H2O, 20 ml 50 % FeCl3, 5 ml HCl 
Solutions A and B are mixed 1:1 
 
 
Ponceau-Säurefucksin-Azophlozin  
 
Masson solution 10 ml and 2 ml Azophlozin-solution and 88 ml 0,2 % acetic acid are 
mixed. 
 
Masson solution 
 
One part solution A (1 g Rubins säurefuchsin and 100 ml H2O are boiled and then 1 ml 
ice acetic is added and solution is filtered) and two parts of solution B (1 g Ponceau de 
Xylidine and 100 ml H2O are boiled and 1 ml iced acetic is added and filtered). 
Azophlozin solution: 0,5 g Azophlozin and 100 ml H2O and 0,2 ml iced acetic is added 
and solution is filtered. 
 
 
Phosphomolybdic acid orange 
 
Phosphomolybdic acid 3 g, Orange G 2 g and 100 ml H2O 
 
 
Lichtgrun 
0,1 g Lichtgrun SF and 100 ml H2O are mixed and 0,2 ml iced acetic is added. 
  
 
